FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W86648317> ?p ?o ?g. }

• W86648317 abstract "The screening strategies for the detection of blood donors potentially able to transmit an infection to the recipient of their blood or blood products have always included clinical, behavioural and laboratory criteria in an attempt to construct a multi-barrier system that most effectively guarantees transfusion safety1. These criteria are necessarily modified over time as further knowledge is acquired and new laboratory tests become available.Hepatitis B virus (HBV) causes the blood-borne viral infection for which serological markers for screening have been available for the longest time. Indeed, the introduction of a test to detect the hepatitis B surface antigen (HBsAg) at the beginning of the 1970s certainly contributed to a drastic reduction in the number of HBV transfusion-transmitted infections. However, despite continuous improvements in the sensitivity of this test, transfusion-related transmission of hepatitis B has not been completely eliminated and in some countries an additional serological investigation (the search for antibodies against HBV core antigen, anti-HBc) was introduced. Testing for these antibodies was initially used as a surrogate marker for the detection of non-A, non-B hepatitis in the mid-1980s, but after the availability of a specific test for hepatitis C virus (HCV), it returned to being of specific relevance in the screening for HBV infection.More recently, a test to detect HBV DNA was introduced for the screening of blood donors. Crucially, this test can detect an acute HBV infection earlier than HBsAg and anti-HBc tests, thus reducing the so called window period during which an infected donors may harbour large amounts of infectious viral particles in the absence of serological markers and/or signs and symptoms of an ongoing infection2. Furthermore, DNA testing allows the identification of a number of donors -including periodic donors-characterised by the absence of HBsAg in the presence of HBV DNA with or without anti-HBs, anti-HBc and/or anti-HBe antibodies. These latter serological profiles are defined as occult HBV infection (OBI) in agreement with the Consensus Conference held in Taormina in 20083. In these cases, the amount of HBV DNA -when detectable- is usually very low (<100–200 IU/mL). On the basis of the serological profile, OBI can be distinguished into seropositive (anti-HBc and/or anti-HBs positive) or seronegative (anti-HBc and anti-HBs negative) types3.The tests that, at present, are mandatory in Italy for the prevention of transfusion-related transmission of HBV include HBsAg (using several commercially available last-generation immunoassays kits) and HBV DNA detection (50% of blood units are tested in pools of 6 samples by Roche Cobas Taqscreen MPX on the Cobas s 201 platform [Roche Instruments Center, Rotkreuz, Switzerland] and 50% in single tests by Novartis Ultrio [Emerville, CA] with comparable analytical and clinical sensitivity4,5). In addition, other serological tests are performed, with a heterogeneous distribution across the country, in part as an additional criterion for the validation of blood components (i.e. anti-HBc) and in part as an evaluation of the immunological status of the donor (i.e. anti-HBs).A national survey organised by the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) in 20096 found that 78 (43%) of 181 Transfusion Services (TS) that replied to a specific questionnaire routinely performed anti-HBc and that 53 of these 78 (68%) TS were located in Northern Italy Regions. In most of the TS (81%) participating in the study, this test was carried out in first-time donors only, while in the remaining (19%) it was carried out in all donors. Fifty percent of the TS that performed this test used a positive result for anti-HBc as a criterion to exclude antibody-positive donors from donating while the remaining TS did not.Thus, there are profound differences in the behaviour of TS, resulting from the persistence of criteria based on serological parameters and criteria derived from the introduction of the new molecular biology tests. In the light of this, SIMTI set up a Working Group charged with the task of defining the screening tests for HBV capable of guaranteeing the highest levels of safety compatible with the possibility of ensuring timely and appropriate transfusion therapy in the specific Italian epidemiological context, with the currently available technology." @default.
• W86648317 created "2016-06-24" @default.
• W86648317 creator A5006578054 @default.
• W86648317 creator A5018630045 @default.
• W86648317 creator A5020921591 @default.
• W86648317 creator A5024307641 @default.
• W86648317 creator A5030321858 @default.
• W86648317 creator A5051914560 @default.
• W86648317 creator A5085389669 @default.
• W86648317 creator A5086033672 @default.
• W86648317 creator A5091506479 @default.
• W86648317 date "2011-10-01" @default.
• W86648317 modified "2023-09-26" @default.
• W86648317 title "Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group." @default.
• W86648317 cites W1492485283 @default.
• W86648317 cites W1536909673 @default.
• W86648317 cites W1551740618 @default.
• W86648317 cites W1907952919 @default.
• W86648317 cites W1969881378 @default.
• W86648317 cites W1975200730 @default.
• W86648317 cites W1977900740 @default.
• W86648317 cites W1980609992 @default.
• W86648317 cites W1984153699 @default.
• W86648317 cites W1989609531 @default.
• W86648317 cites W1991253504 @default.
• W86648317 cites W1993171642 @default.
• W86648317 cites W1995582671 @default.
• W86648317 cites W2006843301 @default.
• W86648317 cites W2017016952 @default.
• W86648317 cites W2025840156 @default.
• W86648317 cites W2028768606 @default.
• W86648317 cites W2032652530 @default.
• W86648317 cites W2042261300 @default.
• W86648317 cites W2042421842 @default.
• W86648317 cites W2050066154 @default.
• W86648317 cites W2053065269 @default.
• W86648317 cites W2054968660 @default.
• W86648317 cites W2060772693 @default.
• W86648317 cites W2063348003 @default.
• W86648317 cites W2063592917 @default.
• W86648317 cites W2073260968 @default.
• W86648317 cites W2080222370 @default.
• W86648317 cites W2095253071 @default.
• W86648317 cites W2096974907 @default.
• W86648317 cites W2100419634 @default.
• W86648317 cites W2104183432 @default.
• W86648317 cites W2114098199 @default.
• W86648317 cites W2116951262 @default.
• W86648317 cites W2120718338 @default.
• W86648317 cites W2121758387 @default.
• W86648317 cites W2126254559 @default.
• W86648317 cites W2136526781 @default.
• W86648317 cites W2143130283 @default.
• W86648317 cites W2145796783 @default.
• W86648317 cites W2147058388 @default.
• W86648317 cites W2149531056 @default.
• W86648317 cites W2156015715 @default.
• W86648317 cites W2164785916 @default.
• W86648317 cites W2166826446 @default.
• W86648317 cites W2172034498 @default.
• W86648317 cites W2204963959 @default.
• W86648317 cites W3149727786 @default.
• W86648317 cites W3158342041 @default.
• W86648317 cites W40064084 @default.
• W86648317 doi "https://doi.org/10.2450/2011.0014-11" @default.
• W86648317 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3200416" @default.
• W86648317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21839007" @default.
• W86648317 hasPublicationYear "2011" @default.
• W86648317 type Work @default.
• W86648317 sameAs 86648317 @default.
• W86648317 citedByCount "9" @default.
• W86648317 countsByYear W866483172012 @default.
• W86648317 countsByYear W866483172013 @default.
• W86648317 countsByYear W866483172014 @default.
• W86648317 countsByYear W866483172017 @default.
• W86648317 countsByYear W866483172019 @default.
• W86648317 countsByYear W866483172020 @default.
• W86648317 countsByYear W866483172021 @default.
• W86648317 countsByYear W866483172023 @default.
• W86648317 crossrefType "journal-article" @default.
• W86648317 hasAuthorship W86648317A5006578054 @default.
• W86648317 hasAuthorship W86648317A5018630045 @default.
• W86648317 hasAuthorship W86648317A5020921591 @default.
• W86648317 hasAuthorship W86648317A5024307641 @default.
• W86648317 hasAuthorship W86648317A5030321858 @default.
• W86648317 hasAuthorship W86648317A5051914560 @default.
• W86648317 hasAuthorship W86648317A5085389669 @default.
• W86648317 hasAuthorship W86648317A5086033672 @default.
• W86648317 hasAuthorship W86648317A5091506479 @default.
• W86648317 hasConcept C119599485 @default.
• W86648317 hasConcept C127413603 @default.
• W86648317 hasConcept C147483822 @default.
• W86648317 hasConcept C159047783 @default.
• W86648317 hasConcept C159654299 @default.
• W86648317 hasConcept C203014093 @default.
• W86648317 hasConcept C2522874641 @default.
• W86648317 hasConcept C2776029263 @default.
• W86648317 hasConcept C2777382497 @default.
• W86648317 hasConcept C2777410769 @default.
• W86648317 hasConcept C2777594644 @default.

• next